Stock Market Reviews

MTNB (Matinas BioPharma Holdings, Inc.) News

Get the latest news, insights, and market updates on MTNB (Matinas BioPharma Holdings, Inc.). Explore the news page 1 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• Matinas BioPharma Holdings, Inc. (MTNB) Restructures Amid Challenges, Focuses on Oral Antifungal MAT2203
  In this article, we will be taking a look at the 15 Best Biotech Penny Stocks to Invest in Right Now. Matinas BioPharma Holdings, Inc. is one of them. Matinas BioPharma Holdings, Inc. (NYSE:MTNB) is a clinical-stage biopharmaceutical company developing oral anti-infective therapies using its proprietary lipid nanocrystal (LNC) platform. Its lead candidate, MAT2203, an […]
  Sep 23, 2025 - $MTNB
• Matinas BioPharma Appoints Seasoned Biotech Leaders to Board of Directors
  BEDMINSTER, N.J., March 11, 2025 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB) today announced the appointment of biotech industry veterans Keith Murphy and Edward Neugeboren to its Board of Directors as independent members, effective March 11, 2025 (the “Effective Date”). In addition, Matthew Wikler, M.D., and Natasha Giordano stepped down from the Board on the Effective Date. “We are thrilled to announce the addition of Keith and Edward to our Board,” stated Jerome
  Mar 11, 2025 - $MTNB
• Matinas BioPharma Announces Agreement for the Acquisition of Preferred Stock and Appointment of Dr. Robin L. Smith to the Board of Directors
  BEDMINSTER, N.J., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB) (the “Company”) today announced that the Company entered into a securities purchase agreement (the “Agreement”) with a certain group of investors (the “Investors”), pursuant to which they agreed to purchase from the Company 3,300 shares of Series C Convertible Preferred Stock (the “Preferred Stock”) and warrants to purchase up to 11,262,808 shares of common stock at a purchase price of $1,0
  Feb 13, 2025 - $MTNB
• Matinas BioPharma Appoints Evelyn D’An to Board of Directors as Audit Committee Chair
  BEDMINSTER, N.J., Feb. 07, 2025 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB) today announced the appointment of Evelyn D’An to its Board of Directors as an independent director and Chair of the Audit Committee, effective Wednesday, February 5, 2025. Ms. D’An is an experienced board director and financial leader with extensive corporate governance, financial oversight, and accounting experience with a range of both public and private companies, where she has served a
  Feb 7, 2025 - $MTNB
• Matinas BioPharma Receives NYSE Noncompliance Notice
  BEDMINSTER, N.J. , Jan. 10, 2025 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB) announces that on January 6, 2025, it received a NYSE American LLC notice indicating that the Company has fallen below certain NYSE American continued listing standards because it failed to hold its annual meeting of stockholders for the fiscal year ending on December 31, 2024, as set forth in Section 704 of the NYSE American Company Guide. The Company intends to hold its annual meeting no
  Jan 10, 2025 - $MTNB